Introduction {#sec1_1}
============

Gastric cancer is among the most common causes of cancer-related death worldwide \[[@B1]\]. The prognosis of locally advanced gastric cancer is poor even if radical gastrectomy with D2 lymphadenectomy is followed by adjuvant chemotherapy \[[@B2]\]. Therefore, combined-modality therapy, such as neoadjuvant chemotherapy, is performed to improve the prognosis, as it can significantly downstage the tumor and safely improve the R0 resection rate of Asian patients \[[@B3]\]. Herein, we report a case of a locally advanced gastric cancer with pancreatic invasion and gastric outlet obstruction that showed a pathological complete response after neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX).

Case Presentation {#sec1_2}
=================

A 74-year-old man was admitted to our hospital, as he was unable to eat owing to pyloric stenosis caused by a large gastric cancer. Upper gastrointestinal endoscopy revealed a type 3 tumor in the region from the gastric angle to the pylorus (Fig. [1](#F1){ref-type="fig"}), and a biopsy indicated a poorly differentiated adenocarcinoma. CT images revealed that the gastric wall was remarkably thickened, and the tumor directly and widely invaded the duodenum and pancreatic head (Fig. [2](#F2){ref-type="fig"}). The carcinoembryonic antigen level was 3.7 ng/mL, and the cancer antigen 19-9 level was 19.1 U/mL. Laparoscopic gastrojejunostomy with incomplete transection of the stomach was performed to improve food passage, and neoadjuvant oxaliplatin (130 mg/m^2^) was administered on the 18th postoperative day in combination with S-1 (80 mg/m^2^/day) for 14 days.

After 3 courses of preoperative chemotherapy as planned, the pyloric mass was not observed on FDG-PET (fluorodeoxyglucose-positron emission tomography), and FDG accumulation was negligible (Fig. [3](#F3){ref-type="fig"}).

Radical distal gastrectomy was performed without any complications. The lymph nodes with suspected pancreatic infiltration that were noted prior to neoadjuvant chemotherapy were scarred and could be dissected from the pancreatic head, thereby avoiding pancreatoduodenectomy, and gross R0 resection could be achieved. The operation time was 316 min, and the amount of blood loss was 208 mL. The patient was discharged from the hospital on the 7th postoperative day, with good postoperative recovery.

Histopathological examination of the resected specimens from both the stomach and the dissected lymph nodes revealed no obvious cancer cells on hematoxylin and eosin staining, although fibrosis with lymphocytic infiltration was extensively observed (Fig. [4](#F4){ref-type="fig"}). Therefore, the patient showed a pathological complete response after neoadjuvant chemotherapy with SOX.

Discussion {#sec1_3}
==========

Many patients with advanced gastric cancer experience recurrence after radical surgery followed by adjuvant chemotherapy, particularly patients with bulky nodal metastases or large type 3 or 4 tumors. Neoadjuvant chemotherapy seems to be one of the effective treatments for advanced gastric cancer. Although preoperative treatment is associated with increased downstaging, thereby increasing the R0 resection rates \[[@B4]\], currently, it is not clear whether neoadjuvant chemotherapy or postoperative adjuvant chemotherapy is better considering the prognosis \[[@B5], [@B6]\].

In the current case, there were no distant metastases or dissemination, and all the factors were indicators of performing resection. However, owing to the presence of duodenal and pancreatic invasion, pancreatoduodenectomy was performed as radical resection; it is a very invasive procedure and may have resulted in a decline in the postoperative quality of life, so it is possible that adequate adjuvant chemotherapy could not be performed. Hence, neoadjuvant chemotherapy was performed, as it would not only allow the patient the opportunity to undergo regular radical distal gastrectomy -- avoiding overinvasive surgery -- but also result in a complete response after chemotherapy with a sufficient dose, thereby resulting in a higher R0 resection rate. Thus, even if radical resection is possible, perioperative chemotherapy might improve the prognosis of patients with highly advanced gastric cancer, such as cT4b tumors with invasion to other organs.

The treatments for symptomatic pyloric stenosis caused by gastric cancer include stent insertion and an alimentary bypass. As we performed bypass surgery on the current patient, the nutritional status markedly improved, with an increase in oral intake, and adequate neoadjuvant chemotherapy could be administered easily. We first performed the modified Devine exclusion, as reported by Schantz et al. \[[@B7]\], with incomplete transection of the stomach as a gastric bypass to evaluate the tumor via endoscopic examination after chemotherapy. Then, after neoadjuvant chemotherapy, we only resected the distal side of the stomach and then performed gastrojejunostomy as part of the modified Devine exclusion in order to reduce surgical invasion as much as possible.

Conclusion {#sec1_4}
==========

Neoadjuvant chemotherapy with SOX resulted in tumor downstaging and might be a multipotent option for the treatment of locally advanced gastric cancer, such as tumors with the invasion of other organs, as it can improve the curative rate and avoid the performance of overinvasive surgery. Nevertheless, clinical trials that evaluate the effectiveness of perioperative chemotherapy in such cases of advanced gastric cancer are being conducted, and the results are awaited \[[@B8]\].
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![Upper gastrointestinal endoscopy revealed a huge type 3 gastric tumor and pyloric stenosis.](cro-0013-0716-g01){#F1}

![**a, b** CT images showing the remarkably thickened gastric wall and the tumor mass (arrowheads) invading the duodenum and pancreatic head before chemotherapy. **c** FDG-PET scan showing that FDG accumulated extremely.](cro-0013-0716-g02){#F2}

![FDG-PET scans showing that FDG accumulation had considerably decreased in the tumor mass after chemotherapy (**c, d**) compared to that observed before chemotherapy (**a, b**).](cro-0013-0716-g03){#F3}

![**a** Resected specimen in which the pyloric lesion was scarred. **b** On histopathological examination after chemotherapy, no cancer cells were observed in the resected specimen, although fibrosis with lymphocytic infiltration was observed.](cro-0013-0716-g04){#F4}
